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http://dx.doi.org/10.1016/j.ccr.2014.06.018SUMMARYLin28a/b are RNA-binding proteins that influence stem cell maintenance, metabolism, and oncogenesis.
Poorly differentiated, aggressive cancers often overexpress Lin28, but its role in tumor initiation or mainte-
nance has not been definitively addressed. We report that LIN28B overexpression is sufficient to initiate
hepatoblastoma and hepatocellular carcinoma in murine models. We also detected Lin28b overexpression
in MYC-driven hepatoblastomas, and liver-specific deletion of Lin28a/b reduced tumor burden, extended
latency, and prolonged survival. Both intravenous siRNA against Lin28b and conditional Lin28b deletion
reduced tumor burden and prolonged survival. Igf2bp proteins are upregulated, and Igf2bp3 is required in
the context of LIN28B overexpression to promote growth. Therefore, multiple murine models demonstrate
that Lin28b is both sufficient to initiate liver cancer and necessary for its maintenance.INTRODUCTION
MicroRNAs (miRNAs) and their protein regulators play important
roles in cancer. One of the most ancient miRNAs is let-7, a 13-
member tumor suppressor miRNA family downregulated in a
large fraction of tumor types (Boyerinas et al., 2010; Roush
and Slack, 2008). Let-7 negatively regulates the translation of on-
cogenes like Myc, Kras, and Hmga2 (Johnson et al., 2005; Mayr
et al., 2007; Sampson et al., 2007). The oncofetal RNA-binding
proteins Lin28a and Lin28b (collectively referred to as Lin28)
inhibit the biogenesis of all let-7s, thereby promoting embryo,
stem cell, and tumor growth (Ambros and Horvitz, 1984; ChangSignificance
Liver cancer is the second most common cause of cancer dea
remains poor. Existing treatments fail to exploit a molecular
for hepatocellular carcinoma has a 3% response rate. Therefor
esis is critical for the development of more effective treatments
ficient to drive aggressive liver tumorigenesis in mice. Additio
siRNA therapy against Lin28b reduces tumor burden and prolo
apeutic target for cancers that overexpress Lin28b.
248 Cancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc.et al., 2009; Shyh-Chang and Daley, 2013; Vadla et al., 2012; Vis-
wanathan et al., 2008). Although some of the effects of Lin28 are
due to let-7 suppression, Lin28 also binds and influences the
translation of many messenger RNAs (Balzer and Moss, 2007;
Cho et al., 2012; Hafner et al., 2013; Jin et al., 2011; Li et al.,
2012; Peng et al., 2011; Wilbert et al., 2012; Xu et al., 2009). In
this way, Lin28 and let-7 are at the center of a large RNA pro-
cessing network that includes other RNA-binding proteins,
non-coding RNAs, and their targets. Given the complexity and
sheer number of interactions within these networks, a critical
problem in the field is to define the phenotypic and therapeutic
implications of disrupting individual components, of whichth worldwide, but scientific and clinical understanding of it
or cellular understanding of the disease, and the best drug
e, understanding new mechanisms behind liver carcinogen-
. Here we show that the RNA-binding protein LIN28B is suf-
nally, we show that both genetic deletion of Lin28a/b and
ngs survival, highlighting this oncogene as a potential ther-
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et al., 2013).
In cancer, Lin28a and Lin28b are aberrantly expressed in a
wide spectrum of tumor types and are associated with advanced
disease and poor prognosis (Viswanathan et al., 2009). Gain and
loss of function studies in cancer cell lines have established that
Lin28 can promote growth, invasion, and metastasis (Guo et al.,
2006; Liang et al., 2010; Wang et al., 2010; You et al., 2013).
Transgenic Lin28b overexpression leads to lymphoma and neu-
roblastoma development in mice, suggesting that, in particular
contexts, Lin28b alone is sufficient to drive cancer (Beachy
et al., 2012; Molenaar et al., 2012). However, it remains unclear
whether Lin28a and Lin28b are relevant to tumor maintenance
in endogenous tumors and, therefore, compelling therapeutic
targets.
In particular, Lin28 and let-7 are frequently and profoundly
dysregulated in liver cancer (Cheng et al., 2013; Guo et al.,
2006; Viswanathan et al., 2009; Wang et al., 2010), which repre-
sents the ideal setting to define the impact of disabling this RNA
network. Hepatocellular carcinoma (HCC), the most common
primary liver tumor, is the second leading cause of cancer death
worldwide and is becoming more prevalent in the United States
as a consequence of chronic hepatitis infection, metabolic syn-
drome, and cirrhosis (Canberk et al., 2013; McMahon, 2009;
Page and Harrison, 2009). Pediatric hepatoblastoma (HB) is a
rare malignant embryonal tumor that shares molecular charac-
teristics with HCC, although it usually arises in the absence of tis-
sue injury (Canberk et al., 2013; Ishak and Glunz, 1967). In both
adult and pediatric settings, treatments are inadequate, and bet-
ter therapeutic targets are needed (European Association for the
Study of the Liver, 2012). Here, using genetically engineered
murine models, we demonstrate that Lin28b overexpression
is both sufficient to induce liver cancer and necessary for
tumor maintenance. We further demonstrate the involvement
of let-7-dependent and -independent mechanisms, thereby
implicating the Lin28/let-7 network as an important pathway in
liver carcinogenesis.
RESULTS
LIN28B Alone Is Sufficient to Drive Liver Tumorigenesis
In Vivo
To assess whether human LIN28B would drive tumorigenesis in
a murine model of liver cancer, we engineered drug-inducible
transgene overexpression using the reverse tetracycline-trans-
activating protein (rtTA) under the control of an ApoE promoter
with hepatocyte-specific regulatory elements (Figure S1A avail-
able online). In this system, ApoE-rtTA mice were crossed to
TRE-LIN28B mice (reported previously by Zhu et al., 2011;
Figure 1A), and double transgenic mice (referred to as ApoE-
LIN28B) were treated with 1mg/ml doxycycline (dox) throughout
development, resulting in high liver-specific LIN28B expression
(Figure S1B). Neonates were jaundiced with slight hepato-
megaly, and, 1 week after birth, LIN28B-overexpressing mice
showed reduced growth relative to TRE-LIN28B single trans-
genic controls (Figure S1C). In postnatal day 4 (p4) pups overex-
pressing LIN28B, histology revealed features of acute liver injury
with cytoplasmic ballooning of hepatocytes and bile stasis in ca-
naliculi (Figure S1D). Phospho-H3 staining showed increasedproliferation in the liver (Figures S1E and S1F). Despite early in-
dications of liver injury, surviving adult ApoE-LIN28B mice
induced with dox did not exhibit significant signs of acute trans-
aminitis, cholestasis, or chronic hepatic synthetic dysfunction
(Figures S1G and S1H).
By 6 months of age, 9 of 9 double transgenic mice, but
no ApoE-rtTA or TRE-LIN28B single transgenic controls, had
multifocal tumors that occupied up to 40% of the liver mass
(Figure 1B). Compared with the control TRE-LIN28B liver
(Figure 1C), tumor histology revealed distinct HCC-like and
hepatoblastoma-like morphologic patterns (Figures 1D–1H).
HCC-like areas were composed of large cells with large nuclei,
coarse chromatin, prominent nucleoli, and granular eosinophilic
cytoplasm (Figures 1D and 1E, yellow arrowheads). In some
areas, the HCC cells showed prominent and abundant fat
vacuoles (Figure 1F). Hepatoblastoma-like areas were consis-
tent with a fetal hepatoblastoma pattern composed of smaller
cells with characteristic oval nuclei with finely clumped chro-
matin, small nucleoli, and eosinophilic cytoplasm (Figures 1G
and 1H). Focally, the fetal hepatoblastoma pattern was contig-
uous with a cholangioblastic pattern composed of irregular
ductal structures (Figure 1H, red arrowhead). Both HCC and
hepatoblastoma regions exhibited embryonic hematopoiesis
(green arrowheads in Figures 1E and 1F), commonly observed
in human hepatocellular neoplasms. Tumors had a high mitotic
rate as measured by phospho-H3 and Ki-67 staining (Figure 1I;
Figure S1I).
ApoE-LIN28B tumor tissue showed greater LIN28B transgene
expression than tumor-adjacent normal tissue, indicating
enhanced expression of the human transgene within the tumor
(Figures 1J–1L). Not surprisingly, mature let-7 biogenesis was
potently suppressed (Figure 1M). Lin28a was not expressed
in these tumors (data not shown). Hmga2, a well known let-7
target, was not derepressed after LIN28B induction in tumor-
adjacent normal tissue or in the tumors themselves (Figure S1J).
Likewise, c-Myc was not increased after LIN28B induction (Fig-
ure S1J). The expression of fetal markers, including a-fetoprotein
(Afp) and Insulin-like growth factor 2 (Igf2), was increased,
whereas Albumin mRNA was potently suppressed (Figures
S1J–S1L), indicating either a block in hepatocyte differentia-
tion or dedifferentiation in tumors. In addition, there was wide-
spread overexpression of imprinted genes, a common feature
of poorly differentiated tumors (Figure S1M). These data
show that LIN28B overexpression is sufficient to drive liver
cancers with morphologic and genetic features of HCC and
hepatoblastoma.
Because ApoE-rtTA and ApoE-LIN28B mice treated with 1g/l
of dox throughout embryogenesis suffered from liver injury and
compromised survival rates, we reduced the dox dose 10-fold
to 0.1g/l, which resulted in the survival of a higher percentage
of double-transgenic mice. To encourage tumor development
with shorter latency, we injected a single 25mg/kg dose of the
HCC-initiating mutagen diethylnitrosamine (DEN) at 2 weeks of
age. We then increased the dox to 1g/l at 3 weeks of age. After
100 days, 1 of 17 TRE-LIN28B mice (6%), 0 of 15 ApoE-rtTA
mice (0%), and 17 of 33 ApoE-LIN28B mice (52%) treated with
DEN harbored grossly visible tumors (Figures S1N and S1O;
the green arrowheads point to tumors). This shows that
LIN28B overexpression is not only sufficient to initiate cancerCancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc. 249
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nant cells established by DEN.
Because Lin28 is known to activate the insulin-phosphatidyli-
nositol 3-kinase-mTOR pathway (Zhu et al., 2011), we asked
whether 2-deoxy-2-(18F) fluoro-D-glucose (FDG) positron emis-
sion tomography (PET)/computed tomography (CT) imaging,
which exploits the fact that cancers are more glucose-avid
than normal tissues, could identify these tumors. In clinical prac-
tice, well differentiated HCCs are not readily detected by PET,
whereas high-grade, poorly differentiated tumors are FDG-avid
(Pant et al., 2013). Although ApoE-LIN28B tumors were difficult
to detect by non-contrast CT alone, they were indeed FDG-
avid (Figure 2). In our murine model, PET/CT imaging provides
confirmation that these ApoE-LIN28B tumors are both
glucose-avid and poorly differentiated, akin to aggressive dis-
ease in humans.
Lin28b Is Aberrantly Activated in Mouse Models of
MYC-Driven Hepatoblastoma
Next, we asked whether Lin28a or Lin28b are overexpressed in
two MYC-driven mouse models, both of which harbor a dox-
inducible human c-MYC transgene (Shachaf et al., 2004). In
the first model (LAP-MYC),MYC is under the control of a tetracy-
cline-dependent repressor expressed from the liver-activated
promoter (LAP) (Figure 3A) (Beer et al., 2004; Shachaf et al.,
2004) so that removal of dox results inMYC expression and hep-
atoblastoma development. This convenient two-transgene
model has a predictable onset of tumorigenesis in the FVB strain
background (Beer et al., 2004). We also employed a second
model (Alb-MYC) in which TRE-MYC is crossed to a Rosa26-
Lox-STOP-Lox-rtTA (RLSL-rtTA); Albumin (Alb)-Cre mouse. In
this strain, MYC is expressed in response to dox after Cre ex-
cises the STOP cassette in albumin-positive cells (Figure 3B).
Although these triple transgenic mice are more challenging toFigure 1. LIN28B Is Sufficient to Drive Liver Tumorigenesis In Vivo
(A) Schematic of the ApoE promoter-driven rtTA transgenic mouse crossed to the
as ApoE-LIN28B) overexpress human LIN28B in hepatocytes.
(B) Gross pathology of a 14-week-old control single-transgenic TRE-LIN28B liver
mass.
(C) Hematoxylin and eosin (H&E) stain of a 14-week-old control single transgenic
(D) H&E stain of an ApoE-LIN28B liver tumor. The yellow arrowhead points to fea
coarse chromatin.
(E) H&E stain of an ApoE-LIN28B tumor showing features of large HCC cells, inclu
of HCC, including large, pleiomorphic cells with prominent nucleoli and coars
arrowhead.
(F) H&E stain of an HCC component of the ApoE-LIN28B liver tumor showing wide
of embryonic hematopoiesis.
(G) H&E stain showing regions of theApoE-LIN28B tumor that resemble fetal hepa
nuclear/cytoplasmic ratios, characteristic oval nuclei with finely clumped chroma
(H) H&E stain showing regions of the ApoE-LIN28B tumor with cholangioblastic a
(I) Immunostaining of normal TRE-LIN28B control liver tissue, ApoE-LIN28B tu
phospho-H3 antibody, demonstrating mitotically active cells.
(J) FLAG immunostaining of normal TRE-LIN28B control liver tissue (left), ApoE-L
(right).
(K) Transgenic LIN28BmRNA levels in control TRE-LIN28B livers (n = 4), ApoE-LIN
(n = 6) as determined by qRT-PCR.
(L) Western blot depicting levels of b-actin and transgenic human LIN28B protei
(M) Levels of mature let-7 family members in control TRE-LIN28B livers (n = 3), Ap
tissue (n = 6) as determined by qRT-PCR.
All data in this figure are represented as mean ± SEM. *p < 0.05, **p < 0.01. Nor
ApoE-rtTA. See also Figure S1.breed, they enable complex genetic intercrossing because tu-
mors arise predictably in mixed genetic strain backgrounds.
Both the ‘‘tet-off’’ LAP-MYCmodel and the ‘‘tet-on’’ Alb-MYC
model overexpressed c-MYC under the control of dox and led to
robust hepatoblastoma formation in the liver (Figure 3C shows a
representative Alb-MYC mouse with tumors). The tumor type
from both models was a mixed embryonal and fetal hepatoblas-
toma with a higher fraction of embryonal hepatoblastoma cells
that are smaller, with higher nuclear-to-cytoplasmic ratio and
oval to angulated hyperchromatic nuclei (Figure 3D). An expres-
sion analysis of normal versus tumor tissue showed high expres-
sion of MYC accompanied by modestly increased levels of
Lin28a (5-fold) and a marked elevation of Lin28b transcript
(1,000- to 10,000-fold; Figure 3E). Immunohistochemistry re-
vealed strong staining for MYC and Lin28b in tumors relative to
control wild-type (WT) liver (Figure 3F), accompanied by signifi-
cant suppression of all measured let-7 family members except
let-7i (Figure 3G).
MYC-driven liver tumors have been reported to be more
aggressive when MYC is activated at earlier developmental
time points (Beer et al., 2004), suggesting that genetic or epige-
netic factors associated with the embryonic state collaborate to
promote high-grademalignancy. Lin28a and b are heterochronic
factors that regulate embryonic growth and metabolism, and we
observed that earlierMYC induction correlated with higher levels
of Lin28b mRNA and protein overexpression (Figure 3H). These
results indicated that Lin28b was associated with a more
aggressive, embryonic tumor type characteristic of an oncofetal
gene expression program.
Deletion of Lin28a/b Increases Latency and Prolongs
Survival in Hepatoblastoma
Prior studies in HCC cell lines have indicated that shRNA sup-
pression of Lin28 reduces cell proliferation in vitro and xenograftTRE-LIN28B transgenic mouse. Double transgenic mice given dox (referred to
and multifocal ApoE-LIN28B liver tumors. Tumors occupy 5%–40% of the liver
TRE-LIN28B liver.
tures of HCC, including large, pleiomorphic cells with prominent nucleoli and
ding prominent eosinophilic globules. The yellow arrowhead points to features
e chromatin. Regions of embryonic hematopoiesis are identified by a green
spread fatty change and vacuolization. The green arrowhead points to a region
toblastoma, characterized by cells smaller than normal hepatocytes with higher
tin, and small nucleoli.
nd ductular differentiation (red arrowhead) along with abundant fatty vacuoles.
mor-adjacent normal liver tissue, and ApoE-LIN28B liver tumor tissue with
IN28B tumor-adjacent normal tissue (middle), and ApoE-LIN28B tumor tissue
28B tumor-adjacent normal liver tissues (n = 3), and ApoE-LIN28B liver tumors
n in control TRE-LIN28B livers and ApoE-LIN28B liver tumors.
oE-LIN28B tumor-adjacent normal livers (n = 3), and ApoE-LIN28B liver tumor
mal control liver refers to single transgenic mice with TRE-LIN28B but lacking
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Figure 2. ApoE-LIN28B Liver Tumors Are Detectable by FDG-
PET/CT
The left panels depict an FDG-PET image (top) and CT scan (bottom) of a
control single transgenic TRE-LIN28B mouse with an absence of signal in the
liver. The middle and right panels illustrate FDG-PET scans (top) and CT scans
(bottom) of two induced ApoE-LIN28Bmice. Signals in the liver are highlighted
with yellow boxes. Signals are also evident in other metabolically active FDG
avid zones, e.g., marrow and heart, as well as in the bladder.
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2009). However, cell lines and human xenografts do not faithfully
model endogenous tumors, and because of off-target effects,
RNAi can be an unreliable method of target validation (Gu
et al., 2012; Qiu et al., 2005). Therefore, we sought to determine
whether the increased Lin28 expression is necessary for tumor
progression by genetically deleting Lin28a and b in the context
of the MYC-driven tumor models. Tumor-bearing TRE-MYC;
RLSL-rtTA; Lin28a+/+; Lin28b+/+; Alb-Cre mice induced on the
day of birth showed a median survival of 40 days, whereas
TRE-MYC; RLSL-rtTA; Lin28aFl/Fl or Fl/-; Lin28bFl/Fl or Fl/-; Alb-
Cremice (double knockout or DKOmice) showed markedly pro-
longed survival, with the majority remaining alive at 150 days
when the experiment was stopped (Figure 4A, p < 0.0001).
Upon gross observation, DKO mice showed reduced tumor
burden with intact regions of normal liver tissue (Figure 4B).
Both Lin28a/bWT and DKO tumors showed embryonal and fetal
hepatoblastoma morphology, indicating that Lin28 loss did not
alter tumor histology (Figure 4C). Curiously, we observed no sig-
nificant differences in cell proliferation, as measured by phos-252 Cancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc.pho-H3 (Figure S2A), but did detect 3-foldmore cells undergoing
apoptosis, as measured by cleaved caspase 3 in DKO tumors
(Figures S2A and S2B).
Importantly,MYCmRNA and protein levels remained intact in
DKO tumors, indicating that the primary oncogenic driver of the
tumormodel was not suppressed transcriptionally or translation-
ally in the absence of Lin28a/b (Figures 4D and 4E). An expres-
sion analysis confirmed that Alb-Cre markedly reduced Lin28b
expression on themRNA and protein levels in DKOmice (Figures
4D and 4E), whereas we detected no significant change in the
low levels of Lin28a mRNA or protein expression (Figures 4D
and 4E). To explore the mechanisms responsible for growth
impairment, we examined markers of differentiation. Lin28a/b
loss resulted in a significant reduction in Igf2 expression (Fig-
ure 4D), consistent with previous reports linking Igf2 expression
and translation to Lin28 (Polesskaya et al., 2007; Zhu et al.,
2010). In contrast, levels of Alb and Afp mRNA did not differ be-
tween WT and DKO tumors (Figure 4D). Analyzing a previously
established 16-gene signature for hepatoblastoma classification
showed no difference in 15 of 16 genes, suggesting that tumor
differentiation was unchanged (Cairo et al., 2008; Figure S2C).
We did observe broad-spectrum increases inmature let-7 levels,
although only let-7g and let-7i were elevated significantly (Fig-
ure 4F). Notably, let-7s were repressed significantly in DKO hep-
atoblastoma when compared to DKO normal liver, but levels of
repression were not as great as in the WT tumors (data not
shown). This suggests that, in tumors formed in the absence of
Lin28a/b, let-7 repression was caused in part by mechanisms
independent of Lin28a and Lin28b and that growth impairment
is not exclusively due to increases in let-7.
In mice, both Lin28a and Lin28b are highly expressed in em-
bryonic tissues but largely silent in adults (Moss and Tang,
2003; Shinoda et al., 2013; Yang andMoss, 2003). We confirmed
that Lin28a and b are expressed in embryonic and neonatal but
not adult liver (Figures 5A–5C). In prior studies, we found that
constitutional Lin28a knockout mice were 10% smaller than
WT littermates and displayed perinatal lethality but no other
obvious phenotypes (Shinoda et al., 2013). Liver-specific
Lin28a and Lin28b DKO mice are also small, but viable, and
have normal liver function (Figures S2D and S2E). Therefore,
our observation of reduced tumorigenicity in Lin28a/b DKO
mice does not appear to be due to developmental defects in
the liver and indicates that liver-specific or systemic anti-Lin28
therapy would be well tolerated.
Igf2bp3 Acts as an Oncogene Downstream of Lin28b
In pursuit of specific Lin28 and let-7 targets that might be
involved in hepatoblastoma and HCC biology, we examined
the Igf2 mRNA binding proteins (Igf2bp1–3), members of a
candidate oncofetal gene family regulated by let-7 (Boyerinas
et al., 2008). IGF2BP3 in particular is highly expressed in human
liver tumors but not in normal liver (Figure S3A) (Wurmbach et al.,
2007), and therefore has been proposed as a sensitive HCC
biomarker (Chen et al., 2013a, 2013b; Jeng et al., 2008; Ni-
schalke et al., 2012; Wachter et al., 2012). Relatively little is
known about the functional activities, biological regulation, and
therapeutic relevance of these genes in cancer. Overexpression
of both mouse Lin28b and human LIN28B in SV40-immortalized
H2.35 hepatocytes led to let-7 suppression and enhanced cell
Figure 3. Lin28b Is Aberrantly Activated in Mouse Models of MYC-Driven Hepatoblastoma
(A) Schematic showing the LAP-tTa; TRE-MYC (or LAP-MYC) transgenic mousemodel. TRE-MYC is driven by the liver-specific LAP promoter when present with
the LAP-tTA transgene in the absence of dox.
(B) Schematic showing the Alb-Cre; RLSL-rtTA; TRE-MYC (or Alb-MYC) triple transgenic mouse model. MYC is expressed after hepatocyte-specific,
Cre-mediated excision of the STOP cassette in albumin-positive cells, followed by the introduction of dox.
(C) Gross pathology of an Alb-MYC-induced liver tumor.
(D) Representative H&E staining of an Alb-MYC-driven liver tumor illustrating a mixed embryonal (left) and fetal (right) hepatoblastoma.
(E) Left, transgenic human c-MYC mRNA levels in wild-type normal liver (n = 8) and Alb-MYC liver tumors (n = 12) as determined by qRT-PCR. Middle, Lin28a
mRNA levels in wild-type normal liver (n = 8) and Alb-MYC liver tumors (n = 12) as determined by qRT-PCR. Right, Lin28bmRNA levels in wild-type normal liver
(n = 8) and Alb-MYC liver tumors (n = 12) as determined by qRT-PCR.
(F) Representative immunostaining of c-MYC (top) and Lin28b (bottom) in wild-type normal liver tissue (left) and Alb-MYC driven liver tumors (right).
(G) Mature let-7 expression levels in wild-type normal liver (n = 8) and Rosa-LSL-rtTA; Alb-MYC-induced tumors (n = 12) as determined by qRT-PCR.
(H) Mouse Lin28a and Lin28bmRNA levels as a function ofMYC induction time in LAP-tTA; TRE-MYC liver tumors as determined by qRT-PCR. The inset shows a
Western blot depicting protein levels of c-MYC, Lin28b, and b-actin in liver tumors induced at p3, p11, or p16.
All data in this figure are represented as mean ± SEM. *p < 0.05, **p < 0.01.
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xenografts (Figures 6A and 6B). In vitro, H2.35 cells that over-
express Lin28b showed elevated mRNA for all three Igf2bp
orthologs (Figure S3E). In vivo, the corresponding xenografts
exhibited robust increases in Igf2bp1 and Igf2bp3 protein levels
(Figure 6C). Tumor tissue from the ApoE-LIN28B hepatoblas-
toma/HCC model, likewise, showed elevated Igf2bp1 and
Igf2bp3, but not Igf2bp2, mRNA and protein levels relative to
ApoE-LIN28B tumor-adjacent normal tissue and normal liver,
also confirmed by immunostaining (Figures 6D–6F). In LAP-
MYC hepatoblastomas, Igf2bp1 and Igf2bp3, but not Igf2bp2,
were highly overexpressed (Figure S3F). Notably, LIN28B and
IGF2BP3 are also coexpressed in advanced, but not early stage,human HCCs (Figure S3G; Wurmbach et al., 2007). Taken
together, these data indicate that LIN28B overexpression is
tightly associated with upregulation of Igf2bp1 and Igf2bp3 in
mouse and human liver cancers.
Multiple lines of evidence support interactions between
Lin28 and Igf2bps, dependent on and independent of let-7
(Boyerinas et al., 2008; Mayr et al., 2007; Polesskaya et al.,
2007). Igf2bp1–3 are known to be directly suppressed by let-7
(Boyerinas et al., 2008). Hafner et al. used photoactivatable-
ribonucleoside-enhanced crosslinking and immunoprecipi-
tation to show that LIN28A and B directly bind IGF2BP1–3
mRNAs in HEK293 cells. Their proteomic analysis also showed
that IGF2BP1–3 protein levels increased when LIN28B wasCancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc. 253
Figure 4. Genetic Deletion of Lin28a/b Increases Latency and Prolongs Survival in MYC-Driven Liver Tumor Models
(A) Kaplan-Meier survival curve of Lin28a/b WT; Alb-MYC mice (yellow, n = 29) or Lin28a/b DKO; Alb-MYC mice (blue, n = 13) dox-induced on the day of birth
(p < 0.0001). Median survival of the Lin28a/b WT; Alb-MYC mice was 40 days, whereas the Lin28a/b DKO; Alb-MYC mice had not achieved median survival at
150 days.
(B) Gross anatomy of Alb-MYC liver tumors with intact Lin28a/b (WT, top) and in the setting of Lin28a/b liver-specific deletion (DKO, bottom). DKO mice were
euthanized at a more advanced age, near their time of death.
(C) H&E staining of Lin28a/b WT (top) and Lin28a/b DKO (bottom) Alb-MYC tumors, showing embryonal (left) and fetal (right) hepatoblastoma histology.
(D) Human c-MYC, mouse Lin28b, Lin28a, Igf2, Albumin, and Afp mRNA levels in Lin28a/bWT; Alb-MYC liver tumors (n = 8) and Lin28a/b DKO; Alb-MYC liver
tumors (n = 8) as determined by qRT-PCR. n.s., not significant.
(E) Western blot illustrating protein levels of Lin28a, Lin28b, c-MYC, and b-tubulin in embryonic day 9.5 (e9.5) mouse embryos (Lin28a/b positive control), WT
testis (Lin28a/b and MYC positive control), Lin28a/bWT normal liver, Lin28a/bWT; LAP-MYC tumors, Lin28a/b DKO normal liver, and Lin28a/b DKO; LAP-MYC
liver tumors.
(F) Expression of mature let-7 family members in Lin28a/b WT (n = 10) and Lin28a/b DKO (n = 14) Alb-MYC tumors.
All data in this figure are represented as mean ± SEM. *p < 0.05, **p < 0.01. See also Figure S2.
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Figure 5. Lin28a/b Expression in the Liver
throughout Development
(A) Lin28b mRNA expression during a liver devel-
opment time course as determined by qRT-PCR.
The heat map illustrates high (red) and low (green)
relative expression in late embryos, neonates, and
young adult livers.
(B) Lin28a and Lin28b protein expression
throughout development in the liver relative to
b-actin protein as determined by Western blot
analysis.
(C) Immunostaining of Lin28b in e14.5 (left), p2
(middle), and p30 (right) liver tissue.
All data in this figure are represented as mean ±
SEM. *p < 0.05, **p < 0.01.
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down. We found that antibody precipitation of FLAG-LIN28B
from both H2.35 cells and BE(2)C neuroblastoma cells copreci-
pitated IGF2BP1–3 proteins, supporting a direct physical inter-
action (Figures S3H and S3I). Furthermore, this interaction was
abrogated upon treatment with RNase, indicating that binding
was dependent on RNA. To determine whether Igf2pb3 is a
downstream effector of Lin28b, we retrovirally overexpressed
LIN28B in H2.35 cells and then performed small interfering
RNA (siRNA) knockdown of Igf2bp3. In the absence of LIN28B
overexpression, Igf2bp3 knockdown reduced cell proliferation,
but not significantly (Figure 6G). However, in the context of
LIN28B overexpression, the reduction in cell proliferation was
significant (Figures 6G and 6H), indicating that LIN28B-positive
cells were more dependent on Igf2bp3. These data suggest
that, in this cell line, LIN28B preferentially requires Igf2bp3
to carry out growth-promoting functions and that these two
RNA-binding protein families can work in concert to promote
liver cancer development.
The Growth of MYC-Induced Hepatoblastoma Is
Impaired after Anti-Lin28b Therapy
We asked whether RNA-based therapy against Lin28b would
antagonize tumor growth, thereby implicating Lin28b as essen-
tial for tumor maintenance. MYC was induced shortly before
birth via dox withdrawal so that 24 day-old mice had multiple
established tumors (Figure S4A, green arrowheads). These
mice were then randomized to no treatment, scrambled control
siRNA, or two different anti-Lin28b siRNAs. Both siLin28b 1
and 2, which target distinct coding sequences within Lin28b,
were effective at knocking down Lin28b overexpression in
H2.35 cells, although siLin28b 1 was more efficient than
siLin28b 2 (Figure S4B). These siRNAs were then injected into
LAP-MYC cohorts intraperitoneally at p14 and intravenously at
p24 and p31. Activity levels and weights of untreated mice
were identical to those of siRNA-treated mice, indicating that
the therapies were not obviously toxic (Figure S4C). Treatment
with siLin28b 1 extended the median survival from 47 to
57 days (p = 0.0006; Figure 7A), and 4 of 15 treated mice
(26%) remained alive at 80 days, well beyond the 47 day median
survival of untreated mice. Treatment with siLin28b 2 also
extended the median survival, but this did not reach statistical
significance (p = 0.054; Figure 7A). Both experimental cohorts,
compared with control cohorts, had reduced abdominal girth,which is well correlated with tumor growth and progression
(p = 0.0040 for siLin28b 1 and p = 0.199 for siLin28b 2; Figures
7B and 7C). Gross and histological examination showed that
mice treated with siLin28b 1 and 2 had significantly less tumor
burden compared with controls at 35 days of age (Figure 7D).
Quantitative RT-PCR (qRT-PCR) confirmed reduced Lin28b
mRNA after siLin28b 1, but not siLin28b 2, treatment, and West-
ern blot analysis showed substantially reduced protein for mice
treated with siLin28b 1 but not for siLin28b 2 (Figures 7E and
7F). Mature let-7 expression did not increase (Figure S4D),
whereas MYC, Igf2bp1 and Igf2bp3 did not decrease in the
experimental groups (Figures 7E and 7F; Figure S4E). The fact
that Igf2bp1 and Igf2bp3 are not altered suggests that their
expression is not entirely regulated by Lin28b and that the
phenotype of Lin28b loss is not always dependent on reduced
Igf2bp1/3 expression. Although siLin28b 1-treated tumors had
a similar number of proliferating cells compared with scrambled
siRNA-treated tumors, siLin28b 1 tumors had 6-fold more cells
undergoing apoptosis than siScramble tumors (Figures 7G and
7H). This is consistent with the higher levels of apoptosis seen
in the Lin28a and Lin28b DKO tumors (Figures S2B and S2C)
and accounts for reductions in tumor growth.
We then validated the siRNA results with conditional genetic
deletion of Lin28b in LAP-MYC mice. To this end, we generated
LAP-tTA; TRE-MYC; Ubiquitin-Cre/ERT2; Lin28b+/+, Lin28bFl/+,
Lin28bFl/Fl, and Lin28bFl/ mice. In the experimental groups
(Lin28bFl/Fl and Lin28bFl/), Lin28b floxed alleles could be
completely excised via tamoxifen exposure, whereas, in the con-
trol groups (Lin28b+/+, Lin28b+/, and Lin28bFl/+), at least one
Lin28b WT allele remained. As in the siRNA experiment, dox
was withdrawn at birth to generate tumors by 1 month of age,
at which point all mice were injected with tamoxifen to condition-
ally delete Lin28b throughout the animal and within tumors. We
first interrogated our tamoxifen regimen to demonstrate that
Cre excision occurred in 90%–100% of hepatocytes in Rosa-
Lox-STOP-Lox-tdTomato reporter mice (Figure S4F). Genotyp-
ing of mice with floxed Lin28b alleles showed > 75% excision
of floxed alleles in 6 of 10 examined mice (60%), and < 50%
excision in 4 of 10mice examined (40%, representative genotyp-
ing is shown in Figure S4G). Conditional deletion of Lin28b in
Lin28bFl/ and Lin28bFl/Fl mice significantly prolonged survival
relative to control mice (Figure 7I, p = 0.019). Eight of seventeen
tumors (47%) from conditional Lin28b knockout mice demon-
strated complete excision of Lin28b (Figure S4G), demonstratingCancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc. 255
Figure 6. Igf2bp3 Acts as an Oncogene
Downstream of Lin28b
(A) Growth curve showing the volume of xeno-
grafts composed of SV40-immortalized H2.35
hepatocytes overexpressing the pBABE empty
vector (n = 5) or FLAG-LIN28B (n = 5) over time.
(B) Gross anatomy of xenografts 50 days post-
injection.
(C) Western blot showing LIN28B, Igf2bp1,
Igf2bp3 and b-tubulin protein levels in H2.35 xe-
nografts with and without LIN28B overexpression.
(D) Left, Igf2bp1 mRNA levels in normal TRE-
LIN28B control liver (n = 4); ApoE-LIN28B tumor-
adjacent normal liver (n = 3); and ApoE-LIN28B
liver tumor (n = 6) tissue as determined by qRT-
PCR. Right, Igf2bp3 mRNA levels in normal
TRE-LIN28B control liver (n = 4); ApoE-LIN28B
tumor-adjacent normal liver (n = 3); and ApoE-
LIN28B liver tumor (n = 6) tissue as determined by
qRT-PCR.
(E) Western blot depicting levels of Igf2bp1,
Igf2bp3, and b-actin protein in normal TRE-
LIN28B control liver and ApoE-LIN28B liver tumor
tissues.
(F) Immunostaining of Igf2bp1 and Igf2bp3 in
normal TRE-LIN28B control liver and ApoE-
LIN28B liver tumors. Dashed lines indicate the
border between ApoE-LIN28B tumor tissue (top
right) and tumor-adjacent normal liver tissue
(bottom left).
(G) Cell proliferation of pBABE control and
LIN28B-overexpressing H2.35 cells treated with
siScramble or siIgf2bp3 for 3 days (n = 3 for each
of the four groups).
(H) Western blot depicting levels of Igf2bp3,
LIN28B, and b-actin in H2.35 cells infected with
retroviruses carrying the pBABE empty vector or
the pBABE-LIN28B overexpression vector and
treated with siRNA against Igf2bp3.
All data in this figure are represented as mean ±
SEM. *p < 0.05, **p < 0.01. See also Figure S3.
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loss of Lin28b. Nevertheless, control mice had a much greater
tumor burden with a median survival of 67 days, whereas condi-256 Cancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc.tionally Lin28b-deleted mice showed a
reduced tumor burden with a median sur-
vival of 99 days (Figure 7I). Together with
the data from our siLin28b experiments,
these findings support Lin28b as a
required maintenance factor in MYC-
driven tumors, suggesting that targeting
Lin28b might be a promising therapeutic
strategy for hepatoblastoma and HCC.
DISCUSSION
We report that Lin28b is sufficient to drive
malignant liver neoplasms and neces-
sary for tumor growth in multiple murine
models. These data demonstrate the
functional importance of LIN28B overex-pression, which has been observed extensively in human liver
cancers (Cairo et al., 2008; Viswanathan et al., 2009; Wang
et al., 2010). Moreover, in aggressive MYC-driven tumors with
Cancer Cell
Lin28b Is Sufficient and Necessary in Liver CancerLin28b overexpression, we have shown that either genetic dele-
tion or siRNA-mediated knockdown of Lin28b prolongs survival,
validating it as an oncogene with essential roles in liver cancer
and, potentially, other malignancies.
Lin28a/b are heterochronic genes that regulate the growth and
metabolic rates of embryonic developmental stages (Moss and
Tang, 2003; Shyh-Chang and Daley, 2013; Yang and Moss,
2003). When expressed at the wrong time or place, they have
the potential to revert adult cell physiology to a more embryonic
state (Shyh-Chang and Daley, 2013). Lin28a can act together
with transcriptional regulators found in embryonic stem cells to
reprogram adult cells to a pluripotent state (Yu et al., 2007). In
cancer, expression of Lin28 in postnatal tissues appears to reac-
tivate programs of embryonic growth and metabolism to drive
tumorigenesis (Viswanathan et al., 2009; Yu et al., 2007). In sup-
port of this hypothesis, ApoE-LIN28B tumors exhibit a poorly
differentiated histology with elements of fetal hepatoblastoma,
poorly differentiated HCC, biliary differentiation, and fetal hema-
topoiesis that mirror the pathology of human liver cancers
(Zhang et al., 2008). Moreover, FDG-PET imaging revealed that
ApoE-LIN28B tumors share metabolic features with glucose-
avid, poorly differentiated tumors. Just as tumor behavior
reflects its cell of origin, it also reflects its temporal origins (Vis-
vader, 2011). Our data give credence to the idea that Lin28b
levels reflect tumors that have reactivated an oncofetal program,
which helps to explain why the Lin28 family is dysregulated in
many pediatric tumors and, potentially, why pediatric and adult
cancers differ in behavior and treatment response.
A major challenge in the RNA processing field is assessing the
impact of individual RNA-binding protein targets versus systems
level effects on many targets. Although Lin28 has a defined and
important target set in the let-7 family, our liver tumor models
demonstrate that Lin28 likely acts through both let-7-dependent
and -independent mechanisms. The ApoE-LIN28B-driven hepa-
toblastoma/HCC mouse model will facilitate future efforts of
determining the critical molecular targets of LIN28B in cancer,
let-7 and otherwise.
Most importantly, using robust endogenous tumor models,
our studies show that LIN28B is sufficient to drive tumorigenesis
and that either siRNA treatment against or conditional genetic
deletion of Lin28b in mice with established liver tumors slows
tumor growth and extends survival. Therefore, Lin28 could
represent a therapeutic target in refractory liver tumors and,
potentially, in other Lin28-positive tumors.
EXPERIMENTAL PROCEDURES
Mice
All animal procedures were based on animal care guidelines approved by the
Institutional Animal Care and Use Committee at Children’s Hospital Boston
and University of Texas Southwestern Medical Center (UTSW). Alb-Cre and
ROSA26-rtTA-IRES-EGFP mice were purchased from The Jackson Labora-
tory. Ubiquitin-Cre/ERT2 mice were a generous donation from the Morrison
laboratory at UTSW. ApoE-rtTAM2; TRE2-Cre transgenic mice expressing
Cre recombinase under the control of a liver-specific, doxycycline-inducible
system were generated by coinjection of 2 transgenes: an 11 kb ApoE-
rtTAM2 transgene and the 2.8 kb TRE2-Cre transgene (provided by Jiafu Ou,
UTSW Department of Molecular Genetics). Cre was not utilized in this report.
ApoE-rtTAmice were crossed to TRE-LIN28Bmice and administered 1 mg/ml
or 0.1mg/ml of dox via the drinking water to induce LIN28B expression.MYC-
driven liver tumors were generated by crossing the TRE-MYC strain with eitherLAP-tTA mice (described previously by Beer et al., 2004) or with RLSL-rtTA
(Belteki et al., 2005); Albumin-Cre mice (obtained from The Jackson Labora-
tory). Mice bearing the LAP-tTA; TRE-MYC genotype were maintained on
1mg/ml of dox, and MYC was induced by withdrawing dox. Mice bearing
the RLSL-rtTA; Alb-Cre; TRE-MYC transgenes were induced at birth with
administration of 1mg/ml dox. The design of conditional Lin28a and Lin28b
knockout mice has been reported previously (Shinoda et al., 2013; Zhu
et al., 2011). Briefly, exon 2 encoding the functional cold shock domain is
flanked by LoxP sites so that expression of Cre recombinase excises the
loci. Themice used contained the PGK-neo selection cassette. For conditional
deletion of Lin28b, tamoxifen (Sigma) was dissolved in corn oil to 20 mg/ml by
sonication for 10 min at 25C and then by incubation at 50C for 10 min.
0.2 mg/g of mouse weight was injected intraperitoneally for three consecutive
days. After a 6 day break, mice were given tamoxifen for twomore consecutive
days. Lin28b floxed and wild-type alleles were genotyped using the primers
AACGCACATTGCAAATACCC (forward) and TTCATCTGGCTCCTTTCTCG
(reverse). Excised alleles were detected using the primers CAGAAAGCGAAG
GAGCAAAG (forward) and TCTTCTCTGGCATTGCTTCA (reverse).
Small Animal PET/CT
Mouse PET/CT imaging was performed using the Siemens Inveon PET/CT
multimodality system (Siemens Medical Solutions) with an effective spatial
resolution of 1.4 mm at the center of the field of view (FOV). Mice were fasted
for 12 hr prior to PET imaging, and each mouse received 140 mCi of FDG in
150 ml of saline intravenously via the tail vain. PET images were acquired
1 hr postinjection. CT images were acquired immediately after PET with the
FOV centered at the shoulder of themouse. CT projections (360 steps/rotation)
were acquired with a power of 80 peak kV, a current of 500 mA, an exposure
time of 145 ms, a binning of 4, and an effective pixel size of 102 mm. PET im-
ages were reconstructed into a single frame using the 3D ordered subsets
expectation maximization (OSEM3D/MAP) algorithm. The CT reconstruction
protocol with a down sample factor of 2, which was set to interpolate bilinearly,
used a Shepp-Logan filter. PET and CT images were coregistered by the man-
ufacturer’s software for analysis.
Cell Lines, Constructs, and Transfection Experiments
BE(2)C and H2.35 cells were purchased from ATCC. Cells were cultured using
standard methods as described by the vendor. Reverse transfection was used
for siRNA knockdown of Igf2bp3 in H2.35 cells. siScramble (Life Technologies,
catalog no. 4390843) or siIgf2bp3 (Life Technologies, catalog no. 4390771
s100444) in Lipofectamine 2000 (Life Technologies, catalog no. 11668019)
was used at a concentration of 25 nM. Forward transfection was employed
for siRNA knockdown of Lin28b in H2.35 cells. siScramble or siLin28b 1 or 2
(Life Technologies, catalog nos. 4390771 s117291and 4390771 s117292) in
Lipofectamine 2000 was used at a concentration of 25nM.
Histology
Tissue samples were fixed in 10% neutral buffered formalin or 4% paraformal-
dehyde and embedded in paraffin. In some cases, frozen sections were made.
Immunohistochemistry and Immunofluorescence
Immunostaining of Frozen Sections
Liver or tumor issue was fixed in 4% paraformaldehyde for 1.5 hr at RT and
then dehydrated overnight in 30% w/v sucrose. Tissue was embedded in
Cryo-gel cutting temperature compound (Tissue-Tek, catalog no. 62806-01)
and frozen on dry ice. Frozen sections were cut at 7 mm, incubated with 3%
H2O2 in methanol for 10 min, blocked with 5% goat serum for 1 hr, and labeled
with primary antibodies overnight at 4C and secondary antibody for 30 min
at room temperature. Nuclear DNA was stained with 300 nM DAPI (Vector
BioLabs, catalog no. NC9029229).
Immunostaining of Paraffin Sections
Tissue was fixed in 4% paraformaldehyde overnight, put into in 75% ethanol
overnight, and embedded in paraffin. Slides were dewaxedwith xylene and re-
hydrated through a series of washes with decreasing percentages of ethanol.
Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) by
placement in a microwave on high for 20 min. Slides were treated with 3%
hydrogen peroxide in methanol for 10 min to inhibit endogenous peroxidase
activity. After blocking with 5% goat serum and the avidin/biotin blocking kitCancer Cell 26, 248–261, August 11, 2014 ª2014 Elsevier Inc. 257
Figure 7. The Growth of MYC-Induced Hepatoblastoma Is Impaired after Anti-Lin28b Therapy
(A) Kaplan-Meier survival curve ofMYC-induced mice randomized to no treatment (n = 29), siScramble (n = 6), siLin28b 1 (n = 15) or siLin28b 2 (n = 6).MYC was
induced 2 days prior to birth by withdrawing dox. Median survival was 46 days for the no treatment group, 47 days for the siScramble group, and 57 days for both
the siLin28b 1 and 2 groups (p = 0.0006 for siLin28b 1 and p = 0.054 for siLin28b 2).
(legend continued on next page)
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Lin28b Is Sufficient and Necessary in Liver Cancer(Vector Laboratories, catalog no. SP-2001), the slides were incubated with pri-
mary antibody overnight at 4C and secondary antibody for 30 min at room
temperature. Detectionwas performedwith the Elite ABC kit and 3030-diamino-
benzidine substrate (Vector Laboratories, catalog no. SK-4100).
Immunofluorescence of Frozen Sections
Liver or tumor issue was fixed in 4% paraformaldehyde for 1.5 hr at RT and
then dehydrated overnight in 30% w/v sucrose. Tissue was embedded in
Cryo-gel cutting temperature compound (Tissue-Tek, catalog no. 62806-01)
and frozen on dry ice. Frozen sections were cut at 7 mm. Nuclear DNA was
stained with 300 nM DAPI (Vector BioLabs, catalog no. NC9029229). The
antibodies used were anti-Lin28a (Cell Signaling Technology, catalog no.
8641), anti-Lin28b (Cell Signaling Technology, catalog no. 5422), anti-Ki-67
(Abcam, catalog no. 15580), anti-phospho-H3 (Cell Signaling Technology, cat-
alog no. 9706), anti-cleaved caspase 3 (Cell Signaling Technology, catalog no.
9661), anti-c-MYC (Sigma, catalog no. M4439), and anti-Afp (R&D Systems,
catalog no. MAB1368).
Western Blot Assay
Cells and tissues were lysed in RIPA buffer and macerated with a pestle. Pro-
teins were separated by 10% polyacrylamide gel and transferred to a polyvi-
nylidene membrane (BioRad, catalog no. 170-4159). The membrane was
blocked overnight at 4C in PBS with Tween 20 (PBST) containing 5% milk
and subsequently probed with primary antibodies overnight at 4C. After incu-
bating the membrane with donkey anti-rabbit or sheep anti-mouse horse-
radish peroxidase-conjugated secondary antibody (GE Healthcare), protein
levels were detected with SuperSignal West Pico or Femto Luminol reagents
(Thermo Scientific, catalog no. 34095). Primary antibodies were prepared in
5% milk in PBST. The following primary antibodies were used: c-MYC (Santa
Cruz Biotechnology, catalog no. sc788), Igf2bp1 (Cell Signaling Technology,
catalog no. 8482), IGF2BP3 (Proteintech, catalog no. 14642-1-AP), and
b-tubulin (Cell Signaling Technology, catalog no. 2128).
RNA Extraction and qRT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, catalog no.
15596018). For qRT-PCR of miRNA or mRNA, cDNA synthesis was performed
with 1 mg of total RNA using the miScript II reverse transcription kit (QIAGEN,
catalog no. 218161) or iScript RT Supermix (BioRad, catalog no. 1708840).
miRNA expression was evaluated using QIAGEN miScript primers. 12.5 ng
of total RNA was used to measure mRNA expression levels via qRT-PCR,
following the protocol as specified in the miScript kit. mRNA levels were
normalized to b-Actin gene expression, whereas miRNA levels were normal-
ized to expression ofU6miRNA. Gene expression levels were measured using
the DDCt method as described previously (Zhu et al., 2011).
In Vivo siRNA Treatment
Ambion in vivo siScramble (Life Technologies, catalog no. 4457289), siLin28b 1
and 2 (Life Technologies, catalog nos. 4457308 s117291 and 4457308
s117292) were diluted to 3 mg/ml in RNase-free water, mixed with complex
buffer and Invivofectamine (Invivofectamine kit, Invitrogen, catalog no.
1377501), incubated for 30 min at 50C, and dialyzed with FLOATALYZER(B) Abdominal circumference (in centimeters) ofMYC-inducedmice 35 days after t
significant.
(C) Pictures of the abdominal region of MYC-induced mice at p35 after treatmen
(D) Representative H&E staining of MYC-induced mice at p35 after treatment wi
(E) Expression levels of Lin28b and c-MYCmRNAs in the tumors ofMYC-induced
normalized to b-actin.
(F) Western blot depicting protein levels of c-MYC, Lin28b, and b-actin in the
siLin28b 2.
(G) Phospho-H3 and cleaved caspase 3 immunostaining of MYC-induced tumor
(H) Number of phospho-H3- and cleaved caspase 3-positive cells per 203 field
(I) Kaplan–Meier survival curve ofMYC-inducedmice with intact Lin28b or conditio
allele after tamoxifen exposure: Lin28b+/+, Lin28b+/Fl, and Lin28b+/. It was poss
tamoxifen exposure: Lin28bFl/ and Lin28bFl/Fl. The median survival time of the L
the Lin28bFl/, Lin28bFl/Fl experimental group was 99 days.
All data in this figure are represented as mean ± SEM. *p < 0.05, **p < 0.01. See(Thermo Fisher Scientific, catalog no. 08607021) for 2 hr in PBS at 25C.
Each 20 g mouse received 0.7 mg/ml per dose. Each mouse was injected
with 100 ml of the prepared solution intraperitoneally at p14, retro-orbitally at
p24, and through the tail vein at p31. Mice were monitored regularly for tumor
growth and survival.
Statistical Analysis
Data are presented as mean ± SEM, and Student’s t test (two-tailed distribu-
tion, two-sample unequal variance) was used to calculate p values. Statistical
significance is displayed as *p < 0.05 or **p < 0.01 unless specified otherwise.
The tests were performed using Microsoft Excel.SUPPLEMENTAL INFORMATION
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